ClinicalTrials.gg
CompletedNCT04798209Updated Jun 21, 2022

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects

A Phase 1 interventional study of ACT-777991 (SAD) and ACT-777991 (MAD) in Healthy, sponsored by Idorsia Pharmaceuticals Ltd.. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Idorsia Pharmaceuticals Ltd. · Phase 1, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Idorsia Pharmaceuticals Ltd. is the lead sponsor of 103 studies on the registry; 4 are open to participants now.

Of its 29 completed or terminated interventional studies of FDA-regulated products, 9 (31%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

General Inclusion Criteria:

  • Signed in a language understandable to the subject prior to any study-mandated procedure.
  • Healthy male (Part A and B) and female subjects (Part B) aged between 18 and 55 years (inclusive) at Screening.
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments, and clinical laboratory tests.
  • Male subjects with a partner who might become pregnant must either be vasectomized or agree to practice adequate from admission to the study site until 3 months after dosing, or the partner must consistently and correctly use a highly effective method of contraception.

Inclusion criteria

Inclusion Criteria for Part B:

  • Women of must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1. They must consistently and correctly use a highly effective method of contraception with a failure rate of less than 1% per year, be sexually inactive, or have a vasectomized partner.
  • Women of non-childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

General Exclusion Criteria:

  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which, in the opinion of the investigator, are likely to interfere with the absorption, distribution, metabolism, or excretion of the study treatment.

Exclusion Criteria for the absorption,distribution, metabolism and excretion (ADME) evaluation:

  • Radiation exposure, excluding background radiation but including diagnostic X-rays and other medical exposures, exceeding 5 milli sievert (mSv) in the last 12 months or 10 mSv in the last 5 years. Occupationally exposed workers, as defined in the relevant Ionising Radiation Regulations, must not participate in the study.
  • Participation in any study involving administration of any Carbon-14 (14C) radiolabeled compound within the 12 months prior to Screening.

Exclusion criteria

Exclusion Criteria for Part B:

  • Pregnant or lactating women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Part A (single ascending dose) Dose A1

    Single dose A1 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A2

    Single dose A2 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A3

    Single dose A3 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A4

    Single dose A4 of ACT-777991 under fasted and fed conditions, separated by at least 14 days.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A5

    Single dose A5 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A6

    Single dose A6 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A7

    Single dose A7 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part A (single ascending dose arm) Dose A8

    Single dose A8 of ACT-777991.

    Drug: ACT-777991 (SAD) · Drug: Placebo (SAD)

  • Experimental
    Part B (multiple ascending dose) Dose B1

    Multiple doses B1 of ACT-777991.

    Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)

  • Experimental
    Part B (multiple ascending dose) Dose B2

    Multiple doses B2 of ACT-777991.

    Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)

  • Experimental
    Part B (multiple ascending dose) Dose B3

    Multiple doses B3 of ACT-777991.

    Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)

  • Experimental
    Part B (multiple ascending dose) Dose B4

    Multiple doses B4 of ACT-777991.

    Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)

  • Experimental
    Part B (multiple ascending dose) Dose B5

    Multiple doses B5 of ACT-777991.

    Drug: ACT-777991 (MAD) · Drug: Placebo (MAD)

  • Experimental
    Part A (single ascending dose) Absolute Bioavailability

    Single dose of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from A4 to A8.

    Drug: 14C-ACT-777991 microtracer (SAD - Absolute Bioavailability) · Drug: Microtracer matching placebo (SAD - Absolute Bioavailability)

  • Experimental
    Part B (multiple ascending dose) ADME

    Multiple doses of ACT-777991 plus a single dose of 14C-ACT-777991. At one of the dose levels from B1 to B5.

    Drug: 14C-ACT-777991 microtracer (MAD - ADME) · Drug: Microtracer matching placebo (MAD - ADME)

Interventions

  • DrugACT-777991 (SAD)

    ACT-777991 administered as hard capsules for oral use.

  • DrugACT-777991 (MAD)

    ACT-777991 administered as hard capsules for oral use, once daily.

  • DrugPlacebo (SAD)

    ACT-777991 matching placebo administered as hard capsules for oral use.

  • DrugPlacebo (MAD)

    Matching placebo administered as hard capsules for oral use, once daily.

  • Drug14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)

    Single dose of 14C-ACT-777991 microtracer, administered intravenously.

  • DrugMicrotracer matching placebo (SAD - Absolute Bioavailability)

    Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.

  • Drug14C-ACT-777991 microtracer (MAD - ADME)

    Single dose of 14C-ACT-777991 microtracer, oral solution..

  • DrugMicrotracer matching placebo (MAD - ADME)

    Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events.

    Time frame: From first dose on Day 1 to Day 4 after the last dose was administered

Secondary outcomes

  1. All cohorts: Area under the plasma concentration-time curve (AUC) from zero to time t of the last measured concentration above the limit of quantification (AUC0-t) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  2. All cohorts: Area under the plasma concentration-time curve (AUC) from zero to infinity (AUC0-inf) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  3. All cohorts: Maximum plasma concentration (Cmax) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  4. All cohorts: Time to reach Cmax (tmax) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  5. All cohorts: Terminal half-life (t1/2) of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  6. Part A (SAD): Absolute bioavailability of ACT-777991

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  7. Part B (MAD): Excretion of radioactivity in urine and feces

    Time frame: Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)

  8. Part B (MAD): AUC during a dosing interval (AUCτ) following the first and the last dose of ACT-777991.

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered

  9. Part A (SAD): Food effect evaluation only: AUC0-inf of ACT-777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

  10. Part A (SAD): Food effect evaluation only: Cmax of ACT-777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

  11. Part A (SAD): Food effect evaluation only: tmax of ACT-777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

  12. Part A (SAD): Food effect evaluation only: t1/2 of ACT 777991 under fed conditions

    Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.

07

Study locations

1 site
  • QPS Netherlands B.V.
    Groningen, 9713 GZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jan 2022, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2021
First posted
Mar 15, 2021
StartActual
Jan 29, 2021
Primary completionActual
Jan 26, 2022
CompletionActual
May 21, 2022
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04798209
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Jan 29, 2021
Primary completion
Jan 26, 2022
Completion
May 21, 2022
Last update
Jun 21, 2022

Study contacts

Clinical Trials
study director · Idorsia Pharmaceuticals Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion